Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-09-15
2008-03-18
Yu, Misook (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S333000, C530S391300, C530S391700
Reexamination Certificate
active
07345151
ABSTRACT:
The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen but not to native triple helical forms of the collagen. Antagonists of the invention can target, for example, denatured collagens type-I, type-II, type-III, type-IV, type-V and combinations thereof. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. Antagonists include monoclonal antibodies referred to as HUI77, HUIV26, and XL313.
REFERENCES:
patent: 5320970 (1994-06-01), Eyre
patent: 5530101 (1996-06-01), Queen et al.
patent: 5541295 (1996-07-01), Barrach et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5763272 (1998-06-01), Naser et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5972623 (1999-10-01), Krane et al.
patent: 6030792 (2000-02-01), Otterness et al.
patent: 6132976 (2000-10-01), Poole et al.
patent: 0 510 949 (1992-10-01), None
patent: 0 921395 (1999-06-01), None
patent: 0992586 (2000-04-01), None
patent: WO9414070 (1994-06-01), None
patent: WO9504282 (1995-02-01), None
patent: WO9744059 (1997-11-01), None
patent: WO9835235 (1998-08-01), None
patent: WO9906840 (1999-02-01), None
Petty et al, J Rheumatology 13:246-253, 1986.
Timpl, R., “Antibodies to Collagens and Precollagens”, Mtehods in Enzymology, 82 Pt A:472-498 (1982).
Jellinek, et al., “Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor”, Biochemistry, 33 (34):10450-10456 (1994).
Tuerk, C., et al., “Systematic Evolution of Ligands by Exponential Enrichment”, RNA Ligands to Bacteriophage T4 DNA Polymerase, Science 249, (Aug. 3, 1990) pp. 505-510.
Ecker, D., et al., Rational Screening of Oligonucleotide Combinatorial Libraries for Drug Discovery, Nucleic Acids Research , vol. 21, No. 8, pp. 1853-1856, (1993).
Wick, G., et al., “Characterization of Antibodies to Basement Membrane (Type IV) Collagen in Immunohistological Studies”, Immunobiology, vol. 156, pp. 371-381 (1979).
Bellon, G, “Quantification and Specific Detection of Collagenous Proteins Using an Enzyme-Linked Immunosorbent Assay and an Immunoblotting for Cyanogen Bromide Peptides”, Analytical Biochemistry, 1985, vol. 150, pp. 188-202.
Brooks, et al., “Antiintegrin αvβ3 Blocks Human Breast Cancer Growth and Angiogenesis in Human Skin”, J. Clin. Invest. Oct. 1995, vol. 96, pp. 1815-1822.
Petitclerc, et al., “Integrin Alpha V Beta 3 Promotes M21 Melanoma Growth In Human Skin By Regulating Tumor Cell Survival”, Cancer Research 59:2724-2730, Jun. 1, 1999.
Borza, Dorin-Bogdan, et al., “Identification of Multiple Cryptic Epitopes on the NC1 Domain of the a3(IV)Collagen Chain,” The Journal of Biological Chemistry, vol. 275, No. 8, Feb. 25, 2000, pp. 6030-6037.
David, Michelle et al., “Hydrophobic Amino Acid Residues Are Critical for the Immunodominant Epitope of the Goodpasture Autoantigen,” The Journal of Biological Chemistry, vol. 276, No. 9, 2001, pp. 6370-6377.
Greenspan, Neil S., et al., “Defining Epitopes: It's Not As Easy As It Seems,” Nature Biotechnology, vol. 17, Oct. 1999, pp. 936-937.
Kalluri, Raghu, et al. “Specificity of Circulating and Tissue-Bound Autoantibodies in Goodpasture Syndrome,” Proceedings of the Association of American Physicians, 1996, pp. 135-139.
Mariuzza, R.A., et al. “The Structural Basis of Antigen-Antibody Recognition,” Am. Rev. Biophys., Biophys. Chem. 1987, pp. 139-159.
Nakanishi, Koichi, et al., “Immunohistochemical Study of a1-5 Chains of Type IV Collagen in Hereditary Nephritis,” Kidney International, vol. 46, 1994, pp. 1413-1421.
Wheatcroft, A.C., “Evidence of In Situ Stability of the Type IV Collagen Triple Helix in Human Inflammatory Bowel Disease Using a Denaturation Specific Epitope Antibody,” Matrix Biology 18, 1999, pp. 361-372.
Yang, Wei-Ping, et al., “CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range,” J. Mol. Biol., 1995, 254, pp. 392-403.
Yoshioka, Kazuo, et al., “Normal Distribution and Abnormalities in X-Linked Alport Syndrome Revealed by Monoclonal Antibody,” American Journal of Pathology, vol. 144, No. 5, 1994, pp. 986-996.
Xu, Jingson, et al., “Generation of Monoclonal Antibodies to Cryptic Collagen Sites by Using Subtractive Immunization,” Hybridoma, vol. 19, Nov. 5, 2000, pp. 375-385.
Brooks Peter C.
Petitclerc Eric
Xu Jingsong
Halvorson Mark
Hogan & Hartson LLP
University of Southern California
Yu Misook
LandOfFree
Antagonists specific for denatured collagen and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonists specific for denatured collagen and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists specific for denatured collagen and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3962232